The company states: “Software revenue growth is expected to range from 10% to 15%. Drug discovery revenue is expected to range from $45 million to $50 million. Software gross margin is expected to range from 74% to 75%. Operating expenses in 2025 are now expected to be lower than 2024. Cash used for operating activities in 2025 is expected to be significantly lower than cash used for operating activities in 2024. For Q3, software revenue is expected to range from $36 million to $40 million.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDGR:
- Meta upgraded, PNC Financial downgraded: Wall Street’s top analyst calls
- Schrodinger assumed with an Equal Weight at Morgan Stanley
- Schrodinger Announces Board Elections and Approvals
- Positive Outlook for Schrödinger: Promising Phase 1 Data and Strategic Growth Initiatives Support Buy Rating
- Schrodinger’s Promising Clinical Data Offset by Market Concerns: Hold Rating Maintained